AUTHORS
Marti Goldenberg, DO, Kathryn Ruble, RN, CPNP, PhD2, Suzanne M. Grieb, PhD, MSPH3, Elizabeth Prince, DO4, Kenneth R Cooke, MD5, C. Patrick Carroll, MD6, Robert Brodsky, MD7, Lydia Pecker, MD8
AFFILIATIONS
1 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
2 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
3 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
4 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
5 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
6 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
7 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
8 Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
ABSTRACT
Introduction: Hematopoietic stem cell transplantation (HSCT) for sickle cell disease (SCD) is increasingly available, particularly with haploidentical approaches that expand donor pools. Despite expanded access, HSCT is underused by young adults (YA) with SCD. Defining information needs of YA with SCD is needed for strategic care coordination and high stakes HSCT decisions.
The purpose of this study was to understand the information needs of YA with SCD referred for HSCT and characterize how information needs change before and after HSCT.
Methods: This was a single-center qualitative descriptive study from November 2024–April 2026 with YA aged 18–35 years who were referred for HSCT. Recruitment was stratified into pre- and post-HSCT (>30 days from HSCT) cohorts. Maximum variation sampling targeted time since HSCT referral; patients were recruited until interviews reached thematic saturation. In semi-structured interviews, we asked YA about the information needed to understand HSCT and navigate treatment and survivorship. Interviews were virtual (~40 minutes). Transcripts were inductively coded in Nvivo software and analyzed for content and themes using qualitative descriptive methods, a pragmatic approach that provides a rich description of patients’ experiences.
Results: We approached and consented 32 eligible subjects; 26 completed interviews. Fourteen were pre-HSCT (donor: 8 haploidentical relative, 6 unknown), 12 were post-HSCT (donor: 4 matched sibling, 8 haploidentical relative). Median age was 25 years (range 19–34); 17 were female, 25 were Black. Insurance coverage was Medicaid (14/26), private (11/26), or international (1/26). Most (25/26) had hemoglobin SS; 1 had HbSβ0-thalassemia. At HSCT referral, all participants had exposure to hydroxyurea; 16 received transfusions. HSCT indications were painful crises (11/26), cerebrovascular disease (7/26), repeat acute chest syndrome (6/26), SCD nephropathy (2/26).
HSCT referrals were from adult (19/26) or pediatric (7/26) SCD clinicians. Among pre-HSCT participants, 7/14 completed an HSCT consultation. Median time from HSCT completion to interview for post-HSCT participants (12/12) was 2.6 years (range 0.19–11.2).
Pre- and post-HSCT participants described HSCT as a non-linear journey during which information needs evolved through referral, evaluation, preparation, and survivorship. Before HSCT, information needs started with framing HSCT within participants’ disease severity and current treatment, and progressed to understanding eligibility and weighing treatment risks, and then navigating the medical, logistical, and social demands of HSCT preparation. After HSCT, participants had new information needs for adapting to life without SCD and survivorship. Participants described periods of progression and pause throughout this journey as disease severity, competing priorities, and logistical barriers changed.
Participants' information priorities differed by cohort, reflecting their stage in the HSCT journey. Pre-HSCT participants deliberated whether their current disease burden made them a HSCT candidate. They weighed HSCT risks against disease-modify therapy use and HSCT feasibility with social, financial, and insurance demands. In contrast, post-HSCT participants had clarity about eligibility. They said worsening disease increased HSCT urgency and helped them prioritize HSCT. Post-HSCT participants recalled similar information needs during preparation but described this stage as a “mad dash” to coordinate practical demands amid progressive disease. After HSCT, participants had unanticipated social and medical needs and wanted “a manual for living without SCD” to navigate identity crises, social reintegration, and long-term health.
In both cohorts, transparent, individualized communication with clinicians helped participants make decisions about HSCT. Participants valued repeated discussions with clinicians that reflected the changing treatment landscape and allowed time for deliberate HSCT planning.
Conclusion: YA with SCD described a nonlinear journey to HSCT and evolving information needs from referral to survivorship. Participants’ information needs reflected their stage in the HSCT journey, disease severity, competing priorities, and logistical barriers. Transparent and repeated discussions with clinicians supported deliberate planning for HSCT. These findings can inform decision-aids that address anticipated choices and barriers before, during, and after HSCT.
DISCLOSURES
Marti Goldenberg, DO: No relevant conflicts of interest to declare.